SCHEMBL2552891

SCHEMBL2552891

CCOC(OCC)C(=N)NCc1cc(Br)ccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.38
SLC6A4 P31645 2/20 0.38
KCNH2 Q12809 2/20 0.38
HPGD P15428 4/20 0.36
TSHR P16473 2/20 0.36
LMNA P02545 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KMT2A Q03164 2/20 0.35
RAB9A P51151 1/20 0.35
MAPT P10636 3/20 0.35
TP53 P04637 1/20 0.35
THRB P10828 1/20 0.34
HTT P42858 1/20 0.34
CCR5 P51681 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALDH1A1 P00352 3/20 0.33
GAA P10253 2/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
DDR1 Q08345 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2554374 0.89 TSHR (0.39) HTR2ASLC6A4KCNH2HPGDTSHR
SCHEMBL2549136 0.85 LMNA (0.36) HPGDLMNASMN1; SMN2KMT2ARAB9A
SCHEMBL2551454 0.83 LMNA (0.51) TSHRLMNASMN1; SMN2KMT2AMAPT
SCHEMBL2552204 0.82 PYCR1 (0.34) LMNASMN1; SMN2KMT2ARAB9AMAPT
SCHEMBL29978873 0.80 ALDH1A1 (0.52) HPGDKMT2ARAB9AHTTNPSR1
SCHEMBL22776522 0.80 ALDH1A1 (0.52) HPGDKMT2ARAB9AHTTNPSR1
SCHEMBL2555265 0.79 KDM1A (0.31) TSHRKMT2AMEN1
SCHEMBL23649659 0.79 LMNA (0.50) TSHRLMNASMN1; SMN2KMT2AMAPT
SCHEMBL2548882 0.78 DDR1 (0.38) LMNAGAACYP1A2DDR1
SCHEMBL557980 0.78 LMNA (0.48) HPGDTSHRLMNASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2552893-B1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-10-29 EP disclosed
US-20130096119-A1 Isoquinolin-3-Ylurea Derivatives BUR DANIEL (CH) 2013-04-18 US disclosed
EP-2552893-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2013-02-06 EP disclosed
WO-2011121555-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096119-A1 Isoquinolin-3-Ylurea Derivatives CLIC1, IRF3, KCNH3 HTR2A 3374/4885SLC6A4 2548/4885KCNH2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.